In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Generex nets $10.55mm through registered direct offering

Executive Summary

Generex Biotechnology (drug delivery technologies) has netted $10.55mm through the registered direct offering (RDO) of 17.2mm common shares at $0.64 (a 4% discount) to accredited investors. The backers also received five-year warrants to buy another 8.6mm shares at $0.76. Midtown Partners & Co. was the placement agent. The company will use the funds to gain regulatory approval for Generex Oral-lyn oral insulin spray in countries including the US, Canada, Mexico, and the EU. Last month the company netted $4.9mm through an RDO.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies